[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"symbiotic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:symbiotic":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627026","alterations-of-gut-derived-uremic-toxins-and-microbiome-metabolites-by-multispecies-synbiotic-100627026",false,"NCT07443280","Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic","Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic Supplementation in Hemodialysis Patients","Inclusion Criteria:\n\n* Adults aged 18 years or older receiving maintenance hemodialysis patients for at least 3 months\n\nExclusion Criteria:\n\n1. Use of probiotic supplements within the last month;\n2. Hospitalization within the past month for acute infections or CKD-related complications;\n3. History of major intestinal surgeries (gastrectomy, cholecystectomy; appendectomy allowed);\n4. Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders;\n5. Use of antibiotics or immunosuppressive therapy within the preceding three months.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis frequently exhibit significant gut microbiota dysbiosis and increased intestinal permeability. These alterations enable the translocation of endotoxins and gut-derived uremic toxins-such as indoxyl sulfate and p-cresyl sulfate-into the systemic circulation, exacerbating systemic inflammation, elevating cardiovascular risk, and accelerating disease progression.\n\nMultispecies synbiotic supplementation has emerged as a promising intervention to restore gut microbial equilibrium, strengthen intestinal barrier function, and reduce the systemic load of harmful microbial metabolites. Through modulation of inflammatory pathways and reduction of circulating uremic toxins, synbiotic hold potential to improve clinical outcomes in this vulnerable population.\n\nAlthough preclinical and some clinical evidence suggests benefits of probiotic therapy, comprehensive clinical trials specifically examining multispecies synbiotic effects on gut inflammatory markers, gut derived metabolite profiles, and uremic toxin levels in hemodialysis patients remain limited. This pilot study aims to address this gap by investigating the biological and clinical effects of a 12-week multispecies regimen in adult maintenance hemodialysis patients.",[26,27,28],"Symbiotic","Uremic Toxins","Gut -Microbiota",[30,31,32,33],"multispecies synbiotic","uremic toxins","gut microbiome","hemodialysis patients","RECRUITING","2026-06-01",{"date":37,"type":38},"2026-06-03","ACTUAL",{"date":40,"type":38},"2026-05-04",{"date":42,"type":20},"2026-12-31",{"name":44,"class":45},"Tungs' Taichung Metroharbour Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":63,"locationsCount":46},"100628407","modulation-of-gut-microbiota-composition-and-gut-permeability-profiles-by-multispecies-synbiotic-supplementation-in-hemodialysis-patients-100628407","NCT07461233","Modulation of Gut Microbiota Composition and Gut Permeability Profiles by Multispecies Synbiotic Supplementation in Hemodialysis Patients",{"count":19,"type":20},[23],"Chronic kidney disease (CKD) patients undergoing maintenance hemodialysis experience profound alterations in their gut microbiota, leading to dysbiosis and increased gut permeability. This disruption facilitates the translocation of endotoxins and gut-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate into the systemic circulation, contributing to heightened systemic inflammation, cardiovascular disease risk, and accelerated CKD progression.\n\nSynbiotic supplementation, particularly multispecies formulations, has emerged as a promising therapeutic strategy to restore gut microbial balance, enhance intestinal barrier integrity, and reduce the systemic burden of deleterious microbial metabolites. These probiotics potentially improve clinical outcomes by modulating inflammatory pathways and decreasing circulating levels of uremic toxins.\n\nDespite these insights, few clinical trials have comprehensively assessed the effects of multispecies synbiotic on fecal microbiome composition, gut permeability and uremic toxin profiles in hemodialysis patients. This pilot study aims to fill this gap by evaluating the modulatory effects of a 12-week multispecies synbiotic intervention.",[26,27,28,56,57],"Gut Permeability","Hemodialysis",[30,33,31,32,59],"gut permeability",{"date":37,"type":38},{"date":40,"type":38},{"date":42,"type":20},{"name":44,"class":45},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":84,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":46},"100630132","multimodal-intervention-for-early-chronic-kidney-disease-in-young-people-dysbiosis-and-inflammation-ckd-100630132","NCT07483697","Multimodal Intervention for Early Chronic Kidney Disease in Young People: Dysbiosis and Inflammation (CKD)","Multimodal Intervention and Its Association With Reduced Dysbiosis and Inflammation in Early Chronic Kidney Disease in Young People: a Prospective Study","CKD","Inclusion Criteria:\n\n* Persistent albuminuria (ACR \\>30 and \\\u003C300 mg\u002Fg).\n* Estimated GFR \\>60 mL\u002Fmin\u002F1.73 m².\n* No identifiable secondary cause of kidney disease.\n\nExclusion Criteria:\n\n* Hypoalbuminemia.\n* Nephrotic syndrome.\n* Persistent macroalbuminuria (ACR \\>300 mg\u002Fg).\n* Secondary or hereditary kidney disease.","14 Years","35 Years",{"count":75,"type":20},200,[23],"Chronic kidney disease (CKD) is a progressive condition associated with substantial morbidity, mortality, and healthcare costs. Early detection and timely intervention are critical to modify disease trajectory, particularly in adolescents and young adults. Emerging evidence supports the role of the gut-kidney axis in CKD progression, whereby intestinal dysbiosis contributes to systemic inflammation and accumulation of microbiota-derived uremic toxins. This randomized controlled clinical trial aims to evaluate whether a multimodal intervention consisting of a controlled diet, structured exercise, and a symbiotic administered for 180 days improves uremic toxin burden, systemic inflammation, and early renal outcomes compared with standard care plus placebo.",[79,80,26,81,82,83],"Exercise","Diet Interventions","CKD Stage 1","CKD Stage 3","CKD Stage 2",[70,85,86,87],"exercise","symbiotic","diet","NOT_YET_RECRUITING","2026-03-17",{"date":91,"type":38},"2026-03-19",{"date":93,"type":20},"2026-04-25",{"date":95,"type":20},"2026-11-03",{"name":97,"class":45},"Centenario Hospital Miguel Hidalgo"]